Ready 8-Ks
26
Latest filing
June 1, 2026, 6:35 PM ET
Top materiality
0.90
Event mix
earnings ×9 · other_material ×7 · debt ×4
Sentiment
6 pos · 3 neg · 17 neu
Latest earnings
reported 2026-Q1
-
Teleflex announces $500M senior notes offering to refinance 2027 notes
Teleflex commenced offering of $500M senior notes due 2032; proceeds plus cash to redeem all $500M of 4.625% notes due 2027.
-
Teleflex enters $2.2B new credit facilities; $1B revolver and $1.2B term loans
Entered new $1B revolver, $500M term A-1, and $700M term A-2 credit facilities; refinances prior credit agreement.
-
Teleflex Q1 revenue up 5.1% pro forma; GAAP EPS $(0.11); maintains FY26 guidance
Revenue from continuing ops $548.3M, up 32.3% reported, +5.1% pro forma adjusted constant currency.
-
Teleflex appoints Jason Weidman as President and CEO effective June 8, 2026
Weidman succeeds interim CEO Stuart Randle, who remains on the board; Weidman to join board on start date.
-
Teleflex responds to Irenic; reaffirms $1.8B sale proceeds for $1B buyback, $800M debt paydown, $50M cost savings
Sale transactions of Acute Care, Interventional Urology, and OEM on track for H2 2026 close.
-
Teleflex updates on OEM and Acute Care divestitures; FTC Second Request for urology deal
OEM HSR waiting period expired March 13, 2026; closing anticipated in Q3 2026.
-
Teleflex reports FY2025 adjusted EPS $6.98; FY2026 guidance $6.25-$6.55; restructuring plan saves $48M-$52M annually
GAAP revenue from continuing ops $1,992.7M (+17.2% YoY); adjusted revenue $1,983.7M (+16.3%).
-
Teleflex CEO Liam Kelly out, interim CEO Stuart Randle appointed; 2025 revenue guide cut
Liam Kelly departs as President and CEO effective Jan 7, 2026; Stuart Randle appointed interim CEO.
-
Teleflex sells Acute Care, Interventional Urology, and OEM businesses for $2.03B; authorizes $1B buyback
Total cash consideration $2.03B: OEM business to Montagu/Kohlberg for $1.5B; Acute Care and Interventional Urology to Intersurgical for $530M.
-
Teleflex Reports Q3 2025 Revenue Growth but GAAP Loss; Lowers Full-Year Guidance
GAAP revenue $913.0M up 19.4% YoY; adjusted revenue $892.9M up 16.8% (adjusted constant currency up 15.3%).
-
Teleflex Q2 adj. EPS $3.73 beats $3.42 YoY; raises FY outlook on BIOTRONIK deal
GAAP revenue $780.9M (+4.2% YoY); adjusted constant currency revenue growth +1.0%.
-
Teleflex increases delayed draw term loan facility by $200M to $700M for Vascular Intervention acquisition
Amendment to Credit Agreement added $200M in delayed draw term loans, bringing total commitments to $700M.
-
Teleflex Q1 adjusted EPS $2.91 (down 9.3% YoY); cuts FY adjusted EPS guidance to $13.20-$13.60 on $55M tariff hit
Q1 revenue $700.7M (-5.0% reported, -3.8% adj constant currency); GAAP EPS $2.07, adjusted EPS $2.91 (down from $3.21).
-
Teleflex reports Q4 adj EPS $3.89 (+15%); plans two-company split and BIOTRONIK acquisition
Q4 GAAP EPS from cont. ops. $(2.95) vs $0.66; adj EPS $3.89 vs $3.38 (+15.1%). Full-year adj EPS $14.01.
-
Teleflex Q3 GAAP EPS $2.36, adj $3.49; cuts FY revenue growth guidance to 2.9-3.4%
Q3 GAAP revenue $764.4M, +2.4% YoY; GAAP diluted EPS $2.36 vs $2.91; adjusted diluted EPS $3.49 vs $3.64.
-
Teleflex enters $200M accelerated share repurchase with Bank of America, scheduled to conclude Q4 2024
Paid $200M to Bank of America on Aug 5, 2024, for initial delivery of shares valued at 80% of repurchase price based on Aug 1 closing price.
-
Teleflex Q2 adjusted revenue $763.5M (+2.7%); raises FY adj EPS guidance to $13.80-$14.20
GAAP revenue $749.7M (+0.9% YoY); adjusted revenue $763.5M (+2.7% YoY, +3.4% constant currency).
-
Teleflex Q1 revenue $737.8M (+3.8% YoY); adjusted EPS $3.21 vs $3.09; raises FY adjusted EPS low end
GAAP diluted EPS from continuing ops $0.33 vs $1.63 prior year, reflecting $1.69 pension settlement charge.
-
Teleflex Reports Q4 2023 Revenue of $773.9M, Full Year Revenue $2,974.5M; Provides 2024 Guidance
Q4 GAAP diluted EPS from continuing operations was $0.66, down from $1.65 in prior year; adjusted EPS was $3.38 vs $3.52.